Colin Lightfoot

B.Sc. Biomedical Science, M.Sc. Infection and Immunity

Colin graduated from the University of Chester with a B.Sc. in Biomedical Science in 2020. Since completing his undergraduate degree, he worked for NHS England as an Associate Practitioner, responsible for testing inpatients for COVID-19 on admission.

Recently Colin was a Study Assistant for Perfectus Biomed, where he grew cell lines and viruses for the testing of mainly commercial cleaning products. He recently completed an M.Sc. in Infection and Immunity at The University of Chester, where his main research focus was antibiotic resistance and the possibility of combatting this with bacteriophage therapy.

See less

Articles from Colin

Mapping the molecular gene signatures of respiratory viruses, including SARS-CoV-2

Researchers compare a large cohort of transcriptomic dataset maps of gene regulation by SARS-CoV-2 infection.

24 Oct 2021

Chemical substance may specifically inhibit both SARS-CoV-2 proteases and human protease

Researchers tested analogs of disulfiram on SARS-CoV-2 Mpro and PLpro to find more efficient and effective inhibitors that take advantage of disulfiram’s mechanism of binding to the cysteine residue.

22 Oct 2021

Mu and C.1.2 variant spike proteins partially resistant to neutralization by vaccine-elicited antibodies

A team of researchers measured the infectivity of SARS-CoV-2 variants C.1.2, Mu, and Delta+501S spike proteins and determined the susceptibility to neutralizing antibodies.

22 Oct 2021

Suggested mechanism of SARS-CoV-2 infection inhibition by Mitoxantrone

A group of researchers performed a drug repurposing screen on an FDA-approved anti-cancer drug named Mitoxantrone.

20 Oct 2021

Safety and oral immunogenicity of a VSV-derived mucosal vaccine against SARS-CoV-2

A team of researchers exploited the known tropism of vesicular stomatitis virus to develop an oral vaccine that expresses the immunogenic SARS-CoV-2 spike glycoprotein in the oral mucosa.

20 Oct 2021

Phase 2 trial shows COVID-19 recombinant protein vaccine elicits promising immunogenicity responses

Researchers performed a large-scale, double-blind, placebo-controlled phase two trial to assess the efficacy, safety, and immune response elicited from vaccination with MVC-COV1901.

19 Oct 2021

SARS-CoV-2 mutations amplify its advantage over host for efficient translation of viral RNAs

A study shows that mutations that SARS-CoV-2 has gained improve its advantage in the efficient translation of viral RNAs.

19 Oct 2021

Research indicates that mRNA vaccine-induced T cells respond robustly to new SARS-CoV-2 variants

To address the gaps in the knowledge, a team of researchers from the University of California and the Gladstone Institute of Virology conducted 39-parameter phenotyping by cytometry by time of flight (CyTOF) on 33 longitudinal specimens from 11 mRNA-vaccinated individuals, of which six had previously been infected and recovered from COVID-19.

18 Oct 2021

Engineered 3D scaffolds of human brown adipose tissue as a new therapeutic strategy for obesity and diabetes

A group of researchers from various institutes in the USA addressed the limitations of BAT therapy by transplanting a low dose of brown adipocytes (BAs) without Matrigel to determine if this could alleviate high-fat diet-induced OB, metabolic symptoms, and T2DM in mice.

18 Oct 2021

Rapid measurement of SARS-CoV-2 spike T-cells

Researchers measure SARS-CoV-2 T-cell responses in individuals vaccinated or in those who developed immunity from a prior natural infection.

12 Oct 2021